Active Biotech’s LION Study Backs Laquinimod’s Potential in Posterior Eye Disease

Active Biotech AB ( (SE:ACTI) ) has provided an update.

Active Biotech has reported that results from its phase I LION study of topical laquinimod eye drops have been published in Ophthalmology Science, demonstrating dose‑related penetration of the drug into both the anterior and posterior segments of the human eye. The hydrogel formulation was well tolerated with no dose‑limiting toxicities, addressing a key challenge in delivering non‑steroidal therapies to the posterior segment for conditions such as non‑infectious uveitis.

The findings support further investigation of laquinimod as a potential treatment for inflammatory eye diseases that affect the posterior segment, an area where existing topical agents have often failed to achieve sufficient intraocular exposure. On the back of these data, Active Biotech is shifting its laquinimod program toward securing a development partner to advance clinical development in eye disorders, which could enhance the asset’s value and reinforce the company’s position in ophthalmic immunomodulation.

More about Active Biotech AB

Active Biotech AB is a Swedish biotechnology company developing first‑in‑class immunomodulatory treatments for oncology and immunology indications with high unmet medical need and significant commercial potential. Its core pipeline includes tasquinimod for myelofibrosis, laquinimod for non‑infectious uveitis using a topical ophthalmic formulation, and naptumomab, a targeted anti‑cancer immunotherapy partnered with NeoTX Therapeutics.

YTD Price Performance: 54.35%

Average Trading Volume: 24,715,826

Technical Sentiment Signal: Sell

Current Market Cap: SEK188.5M

Learn more about ACTI stock on TipRanks’ Stock Analysis page.